European Medicines Agency Recommends Approval of <a href="https://laohu8.com/S/ALVO">Alvotech</a>'s AVT06, Proposed Biosimilar to Eylea®
Alvotech SA, in collaboration with Advanz Pharma, announced that the European Medicines Agency's $(EMA)$ Committee for Medicinal Products for Human Use $(CHMP)$ has adopted a positive opinion recommending market approval for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept 2 mg). This recommendation is a significant step towards marketing the biosimilar in the European Economic Area, which includes the 27 EU member states, Norway, Iceland, and Lichtenstein. The approval is intended for treating various eye disorders, including neovascular age-related macular degeneration and diabetic macular oedema. Alvotech is responsible for the development and commercial supply, while Advanz Pharma holds exclusive commercialization rights in most European countries.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001114182-en) on June 23, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。